251 related articles for article (PubMed ID: 37634997)
1. Narcolepsies, update in 2023.
Barateau L; Pizza F; Chenini S; Peter-Derex L; Dauvilliers Y
Rev Neurol (Paris); 2023 Oct; 179(7):727-740. PubMed ID: 37634997
[TBL] [Abstract][Full Text] [Related]
2. Narcolepsy.
Barateau L; Pizza F; Plazzi G; Dauvilliers Y
J Sleep Res; 2022 Aug; 31(4):e13631. PubMed ID: 35624073
[TBL] [Abstract][Full Text] [Related]
3. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality.
Ruoff C; Rye D
Curr Med Res Opin; 2016 Oct; 32(10):1611-1622. PubMed ID: 27359185
[TBL] [Abstract][Full Text] [Related]
4. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
Mignot E; Lammers GJ; Ripley B; Okun M; Nevsimalova S; Overeem S; Vankova J; Black J; Harsh J; Bassetti C; Schrader H; Nishino S
Arch Neurol; 2002 Oct; 59(10):1553-62. PubMed ID: 12374492
[TBL] [Abstract][Full Text] [Related]
5. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.
Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H
Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Monaca C; Franco P; Philip P; Dauvilliers Y
Rev Neurol (Paris); 2017; 173(1-2):25-31. PubMed ID: 27838095
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.
Andlauer O; Moore H; Hong SC; Dauvilliers Y; Kanbayashi T; Nishino S; Han F; Silber MH; Rico T; Einen M; Kornum BR; Jennum P; Knudsen S; Nevsimalova S; Poli F; Plazzi G; Mignot E
Sleep; 2012 Sep; 35(9):1247-55F. PubMed ID: 22942503
[TBL] [Abstract][Full Text] [Related]
8. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
Baumann CR; Khatami R; Werth E; Bassetti CL
J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):402-4. PubMed ID: 16484654
[TBL] [Abstract][Full Text] [Related]
9. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.
Bassetti CLA; Adamantidis A; Burdakov D; Han F; Gay S; Kallweit U; Khatami R; Koning F; Kornum BR; Lammers GJ; Liblau RS; Luppi PH; Mayer G; Pollmächer T; Sakurai T; Sallusto F; Scammell TE; Tafti M; Dauvilliers Y
Nat Rev Neurol; 2019 Sep; 15(9):519-539. PubMed ID: 31324898
[TBL] [Abstract][Full Text] [Related]
10. The REM-sleep-related characteristics of narcolepsy: a nation-wide multicenter study in Turkey, the REMCON study.
Akyildiz UO; Tezer FI; Koc G; Ismailogullari S; Demir AB; Ak AK; Sunter G; Kara KA; Berktas DT; Sahin A; Azman F; Akcay BD; Gok DK; Yilmaz H; Agan K; Bekmezci Y; Yetkin S; Aksu M; Karadeniz D; Senel GB
Sleep Med; 2022 Jun; 94():17-25. PubMed ID: 35447401
[TBL] [Abstract][Full Text] [Related]
11. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.
Andlauer O; Moore H; Jouhier L; Drake C; Peppard PE; Han F; Hong SC; Poli F; Plazzi G; O'Hara R; Haffen E; Roth T; Young T; Mignot E
JAMA Neurol; 2013 Jul; 70(7):891-902. PubMed ID: 23649748
[TBL] [Abstract][Full Text] [Related]
12. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.
Hong SC; Lin L; Jeong JH; Shin YK; Han JH; Lee JH; Lee SP; Zhang J; Einen M; Mignot E
Sleep; 2006 Nov; 29(11):1429-38. PubMed ID: 17162989
[TBL] [Abstract][Full Text] [Related]
13. Assessment of glymphatic function in narcolepsy using DTI-ALPS index.
Gumeler E; Aygun E; Tezer FI; Saritas EU; Oguz KK
Sleep Med; 2023 Jan; 101():522-527. PubMed ID: 36535226
[TBL] [Abstract][Full Text] [Related]
14. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.
van der Hoeven AE; Fronczek R; Schinkelshoek MS; Roelandse FWC; Bakker JA; Overeem S; Bijlenga D; Lammers GJ
Sleep; 2022 May; 45(5):. PubMed ID: 35554594
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S; Kanbayashi T
Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome analysis of monozygotic Brazilian twins discordant for type 1 narcolepsy: a case report.
Campos JHC; Aguilar ACR; Antoneli F; Truzzi G; Briones MRS; Ferreira RC; Coelho FMS
BMC Neurol; 2022 Nov; 22(1):439. PubMed ID: 36401198
[TBL] [Abstract][Full Text] [Related]
17. Narcolepsy in the older adult: epidemiology, diagnosis and management.
Chakravorty SS; Rye DB
Drugs Aging; 2003; 20(5):361-76. PubMed ID: 12696996
[TBL] [Abstract][Full Text] [Related]
18. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy.
Mattarozzi K; Bellucci C; Campi C; Cipolli C; Ferri R; Franceschini C; Mazzetti M; Russo PM; Vandi S; Vignatelli L; Plazzi G
Sleep Med; 2008 May; 9(4):425-33. PubMed ID: 17681883
[TBL] [Abstract][Full Text] [Related]
19. Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy.
Lopez R; Barateau L; Laura Rassu A; Evangelista E; Chenini S; Scholz S; Jaussent I; Dauvilliers Y
Sleep; 2023 Jan; 46(1):. PubMed ID: 36222741
[TBL] [Abstract][Full Text] [Related]
20. Management of Narcolepsy.
Barateau L; Lopez R; Dauvilliers Y
Curr Treat Options Neurol; 2016 Oct; 18(10):43. PubMed ID: 27549768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
